Nisa Investment Advisors LLC Acquires 4,234 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Nisa Investment Advisors LLC lifted its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 973.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,669 shares of the medical technology company’s stock after buying an additional 4,234 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Alphatec were worth $43,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sei Investments Co. lifted its position in shares of Alphatec by 4.7% during the second quarter. Sei Investments Co. now owns 111,460 shares of the medical technology company’s stock worth $1,165,000 after acquiring an additional 4,976 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Alphatec by 129.1% during the 2nd quarter. AQR Capital Management LLC now owns 283,254 shares of the medical technology company’s stock valued at $2,960,000 after purchasing an additional 159,600 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Alphatec by 8.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 58,257 shares of the medical technology company’s stock worth $609,000 after purchasing an additional 4,755 shares in the last quarter. Creative Planning boosted its stake in Alphatec by 112.7% in the 2nd quarter. Creative Planning now owns 26,440 shares of the medical technology company’s stock worth $276,000 after purchasing an additional 14,007 shares during the period. Finally, SG Americas Securities LLC grew its holdings in Alphatec by 207.7% during the 3rd quarter. SG Americas Securities LLC now owns 44,603 shares of the medical technology company’s stock valued at $248,000 after buying an additional 30,108 shares in the last quarter. 66.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ATEC shares. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th. Barclays increased their target price on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. Finally, Needham & Company LLC boosted their price target on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.56.

Alphatec Price Performance

Shares of NASDAQ:ATEC opened at $11.79 on Friday. The company’s fifty day moving average price is $10.12 and its 200-day moving average price is $8.12. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -9.21 and a beta of 1.41. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $17.34.

Insiders Place Their Bets

In related news, CEO Patrick Miles sold 6,687 shares of Alphatec stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total value of $80,244.00. Following the transaction, the chief executive officer now owns 5,501,715 shares in the company, valued at $66,020,580. This trade represents a 0.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the sale, the executive vice president now owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 115,208 shares of company stock valued at $1,308,335 over the last 90 days. Insiders own 22.80% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.